Postoperative antibiotic therapy patterns in Benign Prostatic Hyperplasia (BPH) patients


  • Aghnia Fuadatul Inayah Department of Pharmacy, Faculty of Health Science, University of Muhammadiyah Malangg, Malang, East Java, Indonesia
  • Rizki Lisya Nugraha Department of Pharmacy, Faculty of Health Science, University of Muhammadiyah Malangg, Malang, East Java, Indonesia
  • Didik Hasmono Department of Pharmacy, Faculty of Pharmacy, Airlangga University, Surabaya, East Java, Indonesia



Benign Prostatic Hyperplasia, Antibiotic prophylactic, Antibiotic empiric, Postoperative


Benign Prostatic Hyperplasia (BPH) is an enlarged prostate disease benign or a condition when the cells are present the prostate gland has an increased proliferation rate. There are several treatment options, including conservative (watchful waiting), medical, and surgery. Antibiotics in BPH cases can be prophylactic antibiotics or empiric antibiotics. This study was  an observational study. The samples were BPH patients who received antibiotics for period January - November 2019. The pattern of prophylactic antibiotic use shows that most of the patients received ceftriaxone therapy. Operation on BPH patients is TURP which is an operation classified into surgery with a clean-contaminated category so that prophylactic antibiotics are required. There are two patterns of use for empiric antibiotics in BPH patients: single (88%) and combination (12%). The pattern of single or combined use is given to patients depending on the complications of the disease and the patient's clinical condition. BPH cases occur in men mostly occurs at the age of 60-74 years. Prophylactic antibiotic therapy in BPH patients, namely ceftriaxone 1 gr IV once daily was 48 patients (90.6%), a broad spectrum. Meanwhile, the most use of empirical antibiotics with a single pattern is Ceftriaxone 1 gr IV twice daily (35.6%).


Download data is not yet available.


Ahmed, A., Azim, A., Gurjar, M., & Baronia, A. K. (2014). Current concepts in combination antibiotic therapy for critically ill patients. Indian Journal of Critical Care Medicine, 18(5), 310-314. doi:10.4103/0972-5229.132495

Atalay, H. A., Canat, L., Alkan, İ., Çakir, S. S., & Altunrende, F. (2017). Prostate-specific antigen reduction after empiric antibiotic treatment does not rule out biopsy in patients with lower urinary tract symptoms: prospective, controlled, single-center study. Prostate International, 5(2), 59-64. doi:10.1016/j.prnil.2017.03.003

Chung, D. Y., & Lee, J. Y. (2019). Recommendations for Antibacterial Prophylaxis in Endourological Procedures. Urogenital Tract Infection, 14(1), 1-8. doi:10.14777/uti.2019.14.1.1

Coker, T. J., & Dierfeldt, D. M. (2016). Acute bacterial prostatitis: Diagnosis and management. American Family Physician, 93(2), 114-120.

Wells, B. G., DiPiro, J. T., Schwinghammer, T. L., & DiPiro, C. V. (2015). Pharmacoterapy Handbook, 9th ed. New York, NY: McGraw-Hill Education.

Fisher, H., Oluboyede, Y., Chadwick, T., Abdel-Fattah, M., Brennand, C., Fader, M., … Pickard, R. (2018). Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial. The Lancet Infectious Diseases, 18(9), 957–968. doi:10.1016/S1473-3099(18)30279-2

Gutiérrez-Castrellón, P., Díaz-García, L., de Colsa-Ranero, A., Cuevas-Alpuche, J., & Jiménez-Escobar, I. (2015). Efficacy and safety of ciprofloxacin in the treatment of urinary tract infections (UTI) in adults: A systematic review with meta-analysis. Gaceta Medica de Mexico, 151(2), 225-244.

Harun, H. (2019). Aspek Laboratorium Benign Prostatic Hyperplasia. Jurnal Ilmiah Kedokteran, 6(3), 1-27.

Ikatan Ahli Urologi Indonesia. (2017). Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak (Benign Prostatic Hyperplasia/ BPH). Jakarta, Indonesia: Authors

Kang, C. I., Kim, J., Park, D. W., Kim, B. N., Ha, U. S., Lee, S. J., ... & Wie, S. H. (2018). Clinical practice guidelines for the antibiotic treatment of community-acquired urinary tract infections. Infection & chemotherapy, 50(1), 67-100doi:10.3947/ic.2018.50.1.67

Katzung, B. G., & Trevor, A. J. (2015). Basic and Clinical Pharmacology, 13th Ed. New York, NY: McGraw-Hill Education.

Khasanah, U., Santoso, A., & Fatiha, C. N. (2020). Evaluation of BPJS and Non BPJS Outpatient Satisfaction for the Quality of Service in the Pharmacy Installation of Tugurejo Regional Hospital of Central Java Province. Sultan Agung Fundamental Research Journal, 1(1), 83-92.

Lawson, K. A., Rudzinski, J. K., Vicas, I., & Carlson, K. V. (2013). Assessment of Antibiotic Prophylaxis Prescribing Patterns for TURP: A Need for Canadian Guidelines?. Canadian Urological Association Journal, 7(7-8), E530. doi:10.5489/cuaj.205

Lee, M. T. G., Lee, S. H., Chang, S. S., Lee, S. H., Lee, M., Fang, C. C., … & Lee, C. C. (2014). Comparative effectiveness of different oral antibiotics regimens for treatment of urinary tract infection in outpatients: An analysis of national representative claims database. Medicine (United States), 93(28), e304. doi:10.1097/MD.0000000000000304

Leibbrand, M., Siefer, S., Schön, C., Perrinjaquet-Moccetti, T., Kompek, A., Csernich, A., … & Kreuter, M. H. (2019). Effects of an Oil-Free Hydroethanolic Pumpkin Seed Extract on Symptom Frequency and Severity in Men with Benign Prostatic Hyperplasia: A Pilot Study in Humans. Journal of Medicinal Food, 22(6), 551-559. doi:10.1089/jmf.2018.0106

Li, Y. H., Li, G. Q., Guo, S. M., Che, Y. N., Wang, X., & Cheng, F. T. (2017). Urinary tract infection in patients undergoing TURP. European Review for Medical and Pharmacological Sciences, 21, 4487-4492.

Lim, K. B. (2017). Epidemiology of clinical benign prostatic hyperplasia. Asian Journal of Urology, 4(3), 148-151. doi:10.1016/j.ajur.2017.06.004

Madersbacher, S., Sampson, N., & Culig, Z. (2019). Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology, 65(5), 458-464. doi:10.1159/000496289

Mangarengi, Y., & Octavia, S. D. R. (2019). Infeksi Saluran Kemih (ISK) Komplikata Di Rumah Sakit Ibnu Sina Makassar. UMI Medical Journal, 4(1), 130-140. doi:10.33096/umj.v4i1.58

Martin, C., Auboyer, C., Boisson, M., Dupont, H., Gauzit, R., Kitzis, M., ... & Pourriat, J. L. (2019). Antibioprophylaxis in surgery and interventional medicine (adult patients). Update 2017. Anaesthesia Critical Care and Pain Medicine, 38(5), 549-562. doi:10.1016/j.accpm.2019.02.017

Montorsi, F., & Mercadante, D. (2013). Diagnosis of BPH and treatment of LUTS among GPs: A European survey. International Journal of Clinical Practice, 67(2), 114-119. doi:10.1111/j.1742-1241.2012.03012.x

Mulyadi, H. T. S., & Sugiarto, S. (2020). Prevalensi Hiperplasia Prostat dan Adenokarsinoma Prostat secara Histopatologi di Laboratorium Patologi Anatomi Rumah Sakit Umum Daerah Cibinong. Muhammadiyah Journal of Geriatric, 1(1), 12. doi:10.24853/mujg.1.1.12-17

Peraturan Menteri Kesehatan Republik Indonesia. (2011). Peraturan Menteri Kesehatan Republik Indonesia Nomor 2406/Menkes/Per/XII/2011 Tentang Pedoman Umum Penggunaan Antibiotik. Jakarta, Indonesia: Authors.

Shin, B., Chung, H. S., Hwang, E. C., Jung, S. Il, & Kwon, D. D. (2017). Antibiotic prophylaxis in radical prostatectomy: Comparison of 2-day and more than 2-day prophylaxis. Journal of Korean Medical Science, 32(6), 1009-1015. doi:10.3346/jkms.2017.32.6.1009

Smith, A. D., Preminger, G., Badlani, G. H., & Kavoussi, L. R. (2019). Smith′s Textbook of Endourology. Hoboken, NJ: John Wiley & Sons Ltd.




How to Cite

Inayah, A. F., Nugraha, R. L., & Hasmono, D. (2021). Postoperative antibiotic therapy patterns in Benign Prostatic Hyperplasia (BPH) patients. Farmasains : Jurnal Farmasi Dan Ilmu Kesehatan, 5(2), 57-62.